These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20937826)

  • 1. Nature of pharmacophore influences active site specificity of proteasome inhibitors.
    Screen M; Britton M; Downey SL; Verdoes M; Voges MJ; Blom AE; Geurink PP; Risseeuw MD; Florea BI; van der Linden WA; Pletnev AA; Overkleeft HS; Kisselev AF
    J Biol Chem; 2010 Dec; 285(51):40125-34. PubMed ID: 20937826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.
    Britton M; Lucas MM; Downey SL; Screen M; Pletnev AA; Verdoes M; Tokhunts RA; Amir O; Goddard AL; Pelphrey PM; Wright DL; Overkleeft HS; Kisselev AF
    Chem Biol; 2009 Dec; 16(12):1278-89. PubMed ID: 20064438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors.
    Ettari R; Bonaccorso C; Micale N; Heindl C; Schirmeister T; Calabrò ML; Grasso S; Zappalà M
    ChemMedChem; 2011 Jul; 6(7):1228-37. PubMed ID: 21506279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.
    Mirabella AC; Pletnev AA; Downey SL; Florea BI; Shabaneh TB; Britton M; Verdoes M; Filippov DV; Overkleeft HS; Kisselev AF
    Chem Biol; 2011 May; 18(5):608-18. PubMed ID: 21609842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits.
    Kessler BM; Tortorella D; Altun M; Kisselev AF; Fiebiger E; Hekking BG; Ploegh HL; Overkleeft HS
    Chem Biol; 2001 Sep; 8(9):913-29. PubMed ID: 11564559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel organic proteasome inhibitors identified by virtual and in vitro screening.
    Basse N; Montes M; Maréchal X; Qin L; Bouvier-Durand M; Genin E; Vidal J; Villoutreix BO; Reboud-Ravaux M
    J Med Chem; 2010 Jan; 53(1):509-13. PubMed ID: 19919035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
    Rydzewski RM; Burrill L; Mendonca R; Palmer JT; Rice M; Tahilramani R; Bass KE; Leung L; Gjerstad E; Janc JW; Pan L
    J Med Chem; 2006 May; 49(10):2953-68. PubMed ID: 16686537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.
    Carmony K; Lee W; Kim KB
    Chembiochem; 2016 Nov; 17(22):2115-2117. PubMed ID: 27605113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of proteasome inhibitors.
    Bo Kim K; Fonseca FN; Crews CM
    Methods Enzymol; 2005; 399():585-609. PubMed ID: 16338383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach.
    Groll M; Huber R
    Biochim Biophys Acta; 2004 Nov; 1695(1-3):33-44. PubMed ID: 15571807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors.
    Steverding D; Spackman RW; Royle HJ; Glenn RJ
    Parasitol Res; 2005 Jan; 95(1):73-6. PubMed ID: 15578221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates.
    Kisselev AF; Goldberg AL
    Methods Enzymol; 2005; 398():364-78. PubMed ID: 16275343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.
    Kisselev AF; Callard A; Goldberg AL
    J Biol Chem; 2006 Mar; 281(13):8582-90. PubMed ID: 16455650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry.
    Genin E; Reboud-Ravaux M; Vidal J
    Curr Top Med Chem; 2010; 10(3):232-56. PubMed ID: 20166955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore modeling technique applied for the discovery of proteasome inhibitors.
    Pautasso C; Troia R; Genuardi M; Palumbo A
    Expert Opin Drug Discov; 2014 Aug; 9(8):931-43. PubMed ID: 24877566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
    Parlati F; Lee SJ; Aujay M; Suzuki E; Levitsky K; Lorens JB; Micklem DR; Ruurs P; Sylvain C; Lu Y; Shenk KD; Bennett MK
    Blood; 2009 Oct; 114(16):3439-47. PubMed ID: 19671918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif.
    Stein ML; Cui H; Beck P; Dubiella C; Voss C; Krüger A; Schmidt B; Groll M
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1679-83. PubMed ID: 24403024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptido sulfonyl fluorides as new powerful proteasome inhibitors.
    Brouwer AJ; Jonker A; Werkhoven P; Kuo E; Li N; Gallastegui N; Kemmink J; Florea BI; Groll M; Overkleeft HS; Liskamp RM
    J Med Chem; 2012 Dec; 55(24):10995-1003. PubMed ID: 23170994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New aldehyde and vinylsulfone proteasome inhibitors for targeted melanoma therapy.
    Vivier M; Rapp M; Galmier MJ; Jarrousse AS; Miot-Noirault E; Leal F; Weber V; Métin J; Sauzière J; Chezal JM; Madelmont JC
    Eur J Med Chem; 2011 Nov; 46(11):5705-10. PubMed ID: 21924528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.